V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016695 | 160018162 | 1.92 | 15.8 | Palliative (P) | 2018-02-27 | 2018-06-05 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | PEMBROLIZUMAB | 100398565 |
| 160016698 | 160018163 | 0.93 | null | Adjuvant (A) | 2019-08-26 | 2019-12-14 | VAC | 02 | N | ETOPOSIDE | 100699335 |
| 160016706 | 160018164 | 0 | 62.3 | 03 | 2020-02-12 | 2020-02-27 | Niraparib | 02 | N | STS RHABDO VIT0910 VINC IRINO TEMOZ | 100928396 |
| 160016710 | 160018165 | 0 | 14.3 | Curative (C) | 2016-12-12 | 2017-01-12 | ATOMIC-MESO TRIAL | Y | N | GEMCITABINE | 100954690 |
| 160016711 | 160018166 | 1.76 | 15.6 | Palliative (P) | 2017-10-21 | 2017-12-31 | Ifosfamide | 02 | null | IFOSFAMIDE | 100851842 |
| 160016712 | 160018167 | 1.61 | 34 | null | 2017-02-01 | 2017-02-03 | ETOP 13-18 BEAT-meso Trial | null | null | NOT MATCHED | 100683768 |
| 160016720 | 160018168 | 1.61 | 70.2 | Palliative (P) | 2018-10-30 | 2018-11-22 | NB HRNBL-1 BUMEL MAT | 01 | N | NB RELAPSED CCLG GUIDELINES TVD | 100139404 |
| 160016721 | 160018169 | null | 67.6 | Curative (C) | 2019-06-06 | 2019-06-13 | Cyclophosphamide PO +Vinorelbine IV | 02 | N | NIRAPARIB | 100121389 |
| 160016722 | 160018170 | null | 70.7 | null | null | 2019-11-13 | STS Rhabdo RMS 2005 Vin Cyclo | 01 | null | CAPECITABINE | 101781879 |
| 160016728 | 160018171 | 1.58 | 14.6 | null | 2019-11-30 | 2019-12-03 | Doxorubicin + Ifosfamide | 02 | null | CREATE TRIAL | 101189672 |
| 160016741 | 160018173 | 1.69 | 17.5 | null | 2017-06-12 | 2017-06-12 | EW EuroEwing 2012 Arm B IE | 01 | null | TRIAL | 101717234 |
| 160016745 | 160018174 | 1.57 | 87 | 03 | 2020-02-05 | 2020-02-20 | Cyclophosphamide + Topotecan | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101560703 |
| 160016747 | 160018175 | 1.62 | 12.7 | null | 2017-03-08 | 2017-03-30 | Cyclophosphamide oral | N | null | DINUTUXIMAB BETA | 100820783 |
| 160016749 | 160018176 | 1.67 | 56.55 | Neo-adjuvant (N) | 2018-06-28 | 2019-05-11 | Niraparib | 02 | N | PAZOPANIB | 100080250 |
| 160016752 | 160018177 | 1.64 | 73 | null | 2018-01-23 | 2018-03-15 | VAI (Ifos 3g/m2) | 02 | null | IRINOTECAN + CISPLATIN + MITOMYCIN | 101614131 |
| 160016764 | 160018178 | 1.73 | 101.4 | Palliative (P) | null | 2021-06-24 | OCTOPUS Trial | 02 | N | CYCLOPHOSPHAMIDE + VINCRISTINE | 100113762 |
| 160016779 | 160018179 | 1.69 | 10 | Curative (C) | 2020-11-13 | 2020-11-30 | Olaratumab | 02 | N | NB HRNBL-1 COJEC IND COURSE C | 100909788 |
| 160016780 | 160018180 | 1.76 | 93.9 | Palliative (P) | 2012-05-01 | 2016-08-12 | NB Rel GD2ch14.18/CHO, IL-2 Isotret | 01 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100363669 |
| 160016784 | 160018181 | 1.66 | 73.5 | Palliative (P) | null | null | EW EuroEwing 2012 Arm B VC | 02 | N | CYCLOPHOSPHAMIDE + VINORELBINE | 101548082 |
| 160016796 | 160018182 | null | 18.6 | Palliative (P) | 2019-07-09 | 2019-07-09 | STS Rhabdomyosarcoma RMS 2005 IVA | 2 | N | ICE | 101456359 |
| 160016802 | 160018183 | 1.89 | 67 | Adjuvant (A) | 2018-03-26 | 2018-04-30 | STS Rhabdo VIT0910 Vinc Irinotecan | 02 | N | NOT MATCHED | 101818931 |
| 160016803 | 160018184 | null | null | null | 2019-02-02 | 2019-02-13 | Cyclophosphamide High Dose | 02 | null | EW EUROEWING 2012 ARM B IE | 101513425 |
| 160016808 | 160018185 | 1.61 | 52.15 | 03 | 2020-02-03 | 2020-02-03 | ICON8B TRIAL | 02 | N | NEMO TRIAL | 101382768 |
| 160016809 | 160018186 | 1.7 | 64.2 | null | 2021-05-24 | 2021-06-13 | Cyclophosphamide + Vincristine | 02 | null | CYCLOPHOSPHAMIDE + VINORELBINE | 100670122 |
| 160016810 | 160018187 | 1.82 | 73.35 | null | 2018-07-13 | 2018-08-03 | NB HRNBL-1 COJEC Ind COURSE B | 02 | null | OLARATUMAB | 101402124 |
| 160016811 | 160018188 | 1.62 | 86 | null | null | null | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | null | null | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 100428216 |
| 160016818 | 160018189 | 0 | null | Curative (C) | 2019-10-03 | 2019-10-11 | IDELALISIB | 02 | N | PEMBROLIZUMAB | 100881694 |
| 160016827 | 160018190 | 0 | 17.9 | Neo-adjuvant (N) | 2018-02-14 | 2018-07-03 | Doxorubicin + Ifosfamide | 02 | N | IVA | 100174492 |
| 160016834 | 160018191 | 1.8 | 74.7 | Palliative (P) | 2017-06-18 | 2018-01-05 | STS Non-Rhabdo EpSSG 2005 IVA | 02 | N | STS RHABDO RMS 2005 | 101549790 |
| 160016838 | 160018192 | 1.62 | 69 | Curative (C) | 2016-09-04 | 2016-09-04 | Doxorubicin + Ifosfamide | 02 | N | DINUTUXIMAB BETA | 100101467 |
| 160016844 | 160018193 | 1.56 | 73.6 | null | 2017-01-09 | 2017-01-20 | ATOMIC-MESO TRIAL | 02 | null | GEMCITABINE | 100517306 |
| 160016852 | 160018194 | 1.66 | 15.8 | Curative (C) | 2017-01-08 | 2017-01-09 | ETOP 13-18 BEAT-meso Trial | 02 | N | IFOSFAMIDE | 100332645 |
| 160016865 | 160018195 | 1.59 | 8.7 | Palliative (P) | 2018-11-10 | 2018-11-19 | EW EuroEwing 2012 Arm B VDC | 02 | N | ICE | 100784015 |
| 160016868 | 160018196 | 1.77 | 72.4 | Curative (C) | 2020-02-17 | 2020-06-23 | STS Rhabdomyosarcoma RMS 2005 IVA | N | N | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 101197738 |
| 160016869 | 160018197 | 1.67 | 48.4 | Curative (C) | 2019-01-30 | 2019-03-03 | Gemcitabine day 1&8 | 02 | N | FLUOROURACIL + IRINOTECAN | 100954955 |
| 160016877 | 160018198 | 1.64 | 32.4 | null | 2018-01-31 | 2018-03-02 | IPM | 02 | null | DOXORUBICIN + IFOSFAMIDE | 100841815 |
| 160016885 | 160018199 | 0 | 48 | Curative (C) | 2020-07-30 | 2020-08-24 | EW EuroEwing 2012 Arm B IE | 02 | null | GEMCARBO | 101028116 |
| 160016889 | 160018200 | 1.64 | 14.6 | null | 2016-12-28 | 2017-03-28 | VAI (Ifos 3g/m2) | 02 | null | NB HRNBL-1 ISOTRETINOIN | 100828540 |
| 160016893 | 160018201 | 1.67 | 68.8 | Palliative (P) | 2020-10-21 | 2020-10-21 | Carboplatin + Etoposide iv&po | 02 | N | GEMCITABINE | 100280433 |
| 160016895 | 160018202 | 1.56 | 63.3 | Palliative (P) | 2018-11-02 | 2018-11-17 | CEDIRANIB | 02 | N | ETOPOSIDE + IFOSFAMIDE | 100586589 |
| 160016901 | 160018203 | 1.01 | 87 | Curative (C) | 2022-05-15 | 2022-05-22 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | NB HRNBL-1 COJEC IND COURSE C | 101762420 |
| 160016921 | 160018205 | 1.64 | 75.3 | null | null | 2021-07-14 | Rucaparib | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100601969 |
| 160016923 | 160018206 | 1.82 | 67.6 | Palliative (P) | 2016-01-08 | 2016-07-17 | CABOZANTINIB | 02 | N | IPILIMUMAB + NIVOLUMAB | 100612536 |
| 160016948 | 160018207 | null | null | Palliative (P) | 2017-08-31 | 2017-08-31 | DACARBAZINE + DOXORUBICIN | 02 | N | BLEOMYCIN + CISPLATIN + ETOPOSIDE | 101428663 |
| 160016953 | 160018208 | 1.69 | 61 | Palliative (P) | 2016-02-25 | 2016-04-10 | GEMCARBO | 02 | N | NB RELAPSED CCLG GUIDELINES TVD | 100054016 |
| 160016955 | 160018209 | 1.57 | 61.4 | null | 2019-02-03 | 2019-02-05 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | STS NON-RHABDO EPSSG 2005 VA | 101863220 |
| 160016959 | 160018210 | 1.86 | 88.2 | null | 2020-04-28 | 2020-05-07 | Etoposide oral | null | null | CYCLOPHOSPHAMIDE | 100659204 |
| 160016965 | 160018211 | 0 | 63.9 | Palliative (P) | 2018-05-06 | 2018-05-09 | VINCRISTINE | 02 | N | CAPECITABINE + OXALIPLATIN | 100019609 |
| 160016971 | 160018212 | 1.8 | 72 | Curative (C) | 2019-12-05 | 2019-12-05 | EpSSG NRSTS 2005 | 02 | N | BEVACIZUMAB + CARBO + PACLITAXEL | 100977599 |
| 160016975 | 160018213 | 1.7 | 16.5 | null | 2019-04-23 | 2019-05-14 | Olaparib | 02 | null | DACARBAZINE | 100761456 |